Pharma TARP: A Troubled Asset Relief Program for Novel, Abandoned Projects in the Pharmaceutical Industry

被引：12

作者：

Bartfai, Tamas ^{[1
]}

Lees, Graham Vaughan ^{[2
]}

机构：

[1] Scripps Res Inst, Mol & Integrat Neurosci Dept, La Jolla, CA 92037 USA

[2] Sci World, Kyrkslatt, Finland

来源：

THESCIENTIFICWORLDJOURNAL | 2011年 / 11卷

基金：

美国国家卫生研究院;

关键词：

TARP; pharmaceutical industry; society; Pfizer; Merck; GlaxoSmithKline; GSK; NIH; NICE; Wall Street; FDA; EMA; government; orphan drugs; intractable epilepsy; cancer pain; neuropathic pain; obesity; type-2; diabetes; schizophrenia;

D O I：

10.1100/tsw.2011.61

中图分类号：

X [环境科学、安全科学];

学科分类号：

08 ; 0830 ;

摘要：

Within days of each other, Pfizer, Merck, and GlaxoSmithKline announced that they will focus on a few therapeutic areas only and abandon others entirely. Pfizer alone will close well over a hundred drug development projects that have reached two-thirds of the way to launch. The programs are deemed to be too risky and not lucrative enough for Big Pharma in the current climate. Society has a real need for the drugs that are no longer going to be developed for, among others, drug-resistant epilepsy, neuropathic and cancer pain, type-2 diabetes, obesity, and schizophrenia. The authors propose a radical response by the U.S. government and the National Institutes of Health to rescue these abandoned projects, and to continue selected programs for drug approval by the U.S. Food and Drug Administration and the European Medicines Agency. The investment required is small compared to the Troubled Asset Relief Program bank bail out, but the return on investment in financial terms and in satisfying societal needs makes this proposal attractive.

引用

页码：454 / 457

页数：4

共 17 条

[11] Estrogen therapy and coronary-artery calcification [J].

Manson, JoAnn E. ;

Allison, Matthew A. ;

Rossouw, Jacques E. ;

Carr, J. Jeffrey ;

Langer, Robert D. ;

Hsia, Judith ;

Kuller, Lewis H. ;

Cochrane, Barbara B. ;

Hunt, Julie R. ;

Ludlam, Shari E. ;

Pettinger, Mary B. ;

Gass, Margery ;

Margolis, Karen L. ;

Nathan, Lauren ;

Ockene, Judith K. ;

Prentice, Ross L. ;

Robbins, John ;

Stefanick, Marcia L. ;

Rossouw, J. E. ;

Ludlam, S. ;

Cochrane, B. B. ;

Hunt, J. R. ;

Lund, B. ;

Prentice, R. ;

Carr, J. J. ;

O'Rourke, C. ;

Du, L. ;

Pillsbury, S. ;

Hightower, C. ;

Ellison, R. ;

Tan, J. ;

Wassertheil-Smoller, S. ;

Magnani, M. ;

Noble, D. H. ;

Dellicarpini, T. ;

Manson, J. E. ;

Bueche, M. ;

McGinnis, A. D. ;

Rybicki, F. J. ;

Assaf, A. R. ;

Sloane, G. ;

Phillips, L. S. ;

Butler, V. ;

Huber, M. ;

Vitali, J. ;

Hsia, J. ;

LeBrun, C. ;

Palm, R. ;

Embersit, D. ;

Whitlock, E. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (25) :2591-2602

[12]

Mijuk G., 2010, WALL STREET J 1117

[13]

Pocock N., 2010, EMEA NEW TEMPORARY T

[14]

Pollack A., 2010, NY TIMES 0415

[15]

Scheer R., 2010, COLUMBIA DAILY 1127

[16]

Silverman E., 2011, PHARMALOT 0119

[17] Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy [J].

Stefanick, ML ;

Anderson, GL ;

Margolis, KL ;

Hendrix, SL ;

Rodabough, RJ ;

Paskett, ED ;

Lane, DS ;

Hubbell, FA ;

Assaf, AR ;

Sarto, GE ;

Schenken, RS ;

Yasmeen, S ;

Lessin, L ;

Chlebowski, RT .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (14) :1647-1657

← 1 2 →